Leprosy disabilities: The impact of multidrug therapy (MDT)

International Journal of Dermatology

Volumn 36, Issue 8, 1997, Pages 561-572

  Ladhani, Shamez ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE;

DISABILITY; DRUG EFFICACY; EARLY DIAGNOSIS; HEALTH EDUCATION; INCIDENCE; LEPROSY; PATIENT COMPLIANCE; PREVALENCE; REHABILITATION; RELAPSE; REVIEW; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0030987510     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1997.00266.x     Document Type: Review

References (162)

1. Ridley DS, Jopling WH. Classification of leprosy according to immunity; a five-group system. Int J Lepr 1966; 34: 255-273.
2. Anonymous. Chemotherapy of leprosy for control programmes. WHO Tech Rep Ser 657, 1982.
3. Sehgal VN, Lamba PA. Ocular changes in leprosy. Int J Dermatol 1990; 29: 175-182.
4. Watson JM. Disability control in a leprosy control programme. Lepr Rev 1989; 60: 169-177.
5. Bourrel P. Surgical rehabilitation. Lepr Rev 1991; 62: 241-254.
6. Dastur DK. Cutaneous nerves in leprosy; relationship between histopathology and cutaneous sensibility. Brain 1955; 78: 615-633.
7. Kyriakidis MK, Noutsis CG, Robinson-Kyriakidis CA, et al. Autonomie neuropathy in leprosy. Int J Lepr 1983;551: 331-335.
8. Srinivasan H. Trophic ulcers in leprosy II -intrinsic muscles of the foot and trophic ulcers. Lepr India 1964; 36: 110-118.
9. Smith WCS. The epidemiology of disability in leprosy including risk factors. Lepr Rev 1992.; 63 Suppl: 135-305.
10. Anonymous. A Guide to Leprosy Control. Geneva: World Health Organization, 1980.
11. Srinivasan H, Rao KS, Shanvigam N. Steroid therapy in recent "quiet nerve paralysis." Indian J Lepr 1981; 54: 411-419.
12. Tiendrebeogo A, Toure I, Zerbo PJ. A survey of leprosy impairments and disabilities among patients treated by MDT in Burkina Faso. hit J Lepr 1996; 64: 15-2.5.
13. De Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation of WHO-MDT of fixed duration at ALERT, ETHOPIA: the AMFES project -I. MDT course completion, case-holding and another score for disability grading. Lepr Rev 1994; 65: 305-319.
14. Gelber RH, Fakuda K, Byrd S, et al. Clinical trial of minocycline in lepromatous leprosy. Br Med J 1992; 304: 91-92.
15. Lopez-Bravo L, Ratard RC. Leprosy disabilities in the New Hebrides. Lepr Rev 1977; 48: 2.47-2.60.
16. Mishra B, Ramu G, Chauhan VS, et al. Leprosy deformities. Indian J Lepr 1988; 60: 2.60-161.
17. Sehgal VN, Sharma PK. Pattern of deformities/ disabilities in urban leprosy. Indian J Lepr 1985; 57: 183-191.
18. Girdhar M, Arora SK, Mohan L, Mukhija RD. Pattern of leprosy disabilities in Gorakhpur (Utar Pradesh). Indian J Lepr 1989; 61: 503-513.
19. Htoon MT, Win Z. Disability among rural leprosy patients in Myanmar. Int J Lepr 1994; 62: 126-119.
20. Dharmendra. Rehabilitation of leprosy patients in a comprehensive control programme in Gudiyatham Taluk of Tamil Nadu. Lepr India 1976; 48: 177-182.
21. Kumar JHR, Verghese A. Psychiatric disturbances among leprosy patients: an epidemiological study. Int J Lepr 1980:48: 431-434.
22. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and therapy; experience in the Leprosy Control Program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethopia. Int J Lepr 1991; 60: 173-184.
23. Gupte MD. Dapsone treatment and deformities; a retrospective study. Lepr India 1979; 51: 118-235.
24. Lienhardt C, Fine PEM. Type i reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev 1994; 65: 9-33.
25. Chaturvedi RM. Epidemiological study of leprosy in the Malawinan suburb of Bombay. Lepr Rev 1988; 59: 113-110.
26. lyere BB. Leprosy deformities: experience in Molai Leprosy Hospital, Maduguri, Nigeria. Lepr Rev 1990; 61: 171-179.
27. Boerrigter P, Ponnighaus JM, Fine PEM. Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 1988; 56: 408-417.
28. Lombardi C. Evaluation of leprosy epidemiology in 12. countries of the Americas, 1980-1983. Bull PAHO, 1989; 13: 284-294.
29. Kikuchi I. Hansen's disease patients: responses to stigma and segregation in Kumamoto, Japan. Int J Dermatol 1994; 33(2.): 142-145.
30. Jopling WH. Leprosy stigma. Lepr REv 1991; 62: 1-12.
31. Nathan R. Archaic leprosy law under attack. Nat Med 1995; 1: 617.
32. Wolcott RR, Ross H. Exacerbation of leprosy during present day treatment. Int J Lepr 1953; 2I: 437-440
33. Noordeen SK. A look at world leprosy. Lepr Rev 1991; 62: 72-86.
34. Britton WJ, Hargrave JC. Leprosy in the tropics and Australia. Med J Anst 1993; 159: 326-330.
35. Sreevatsa, Girdhar BK, Desikan KV. Screening for drugresistant strains of M. leprae in lepromatous patients under multidrug therapy. Indian J Med Res 1988; 87: 139-143.
36. Pattyn SR, Husser JA, Baquillon G, et al. Evaluation of five treatment regimens using either dapsone monotherapy or several doses of rifampicin in the treatment of paucibacillary leprosy. Lepr Rev 1990; 61: 151-156.
37. Deitrich M, Gaus W, Kern P, Meyers WM. An international randomized study with long-term followup of single versus combination chemotherapy of multibacillary leprosy. Antimicrob Agents Chemother 1994; 38: 2249-2257.
38. Deitrich MJ, Rangaraj J, Ganapati R, et al. Combination therapy vs monotherapy in BL and LL patients: a prospective randomized multicenter study (Abstract). Int J Lepr 1989; 57 Suppl.: 426.
39. Irudayaraj PP, Aschhoff M. Assessment criteria and multidrug therapy (Abstract). Int J Lepr 1989; 57 Suppl.: 426.
40. THELEP (Subcommittee of Clinical Trials, Scientific Working Group on the Chemotherapy of Leprosy). Response of THELEP trial patients to combined drug, regimens (Abstract). Int J Lepr 1989; 57 Suppl.: 428.
41. Becx-Bleumink M. Priorities of the future and prospects for leprosy control. Int J Lepr 1993; 61: 82-101.
42. Noordeen SK, Lopez-Bravo L, Sundaresan TK. Estimated number of leprosy cases in the world. Lepr Rev 1992; 63: 282-287.
43. WHO. Progress towards eliminating leprosy as a public health problem. WHO Wkly Epidemiol Rec 1994; zo/ 21: 145-151, I53-I57-
44. Britton WJ. Immunology of leprosy. Trans Roy Soc Trop Med Hyg 1993; 87: 508-514.
45. Lienhardt C, Fine PEM. Controlling leprosy: multidrug treatment is not enough alone. Br Med J 1992; 305: 206-207.
46. Girdhar BK. Multidrug therapy in leprosy and its future components. Indian J Lepr 1994; 66: 179-209.
47. Noordeen SK. Elimination of leprosy as a public health problem. Lepr Rev 1992; 63: 1-4.
48. Fine PEM. Reflections on the elimination of leprosy. Int J Lepr 1992; 60: 71-80.
49. Anonymous. Leprosy disabilities: magnitude of the problem. WHO Wkly Epidemiol Rec 1995; 70: 269-276.
50. Gilbody JS. Aspects of rehabilitation in leprosy. Int J Lepr 1992; 60: 608-640.
51. Boerrigter G, Ponnighaus JM. Does the introduction of WHO-MDT influence trends in the incidence of leprosy? -the Malawian experience. Lepr Rev 1993; 64: 227-235.
52. Theuvenet WJ, Soares D, Baral JP, et al. Mass survey of leprosy in Lalitpur district, Nepal. Int J Lepr 1994; 62: 256-261.
53. Saha SP, Das KK. Disability pattern amongst cases in urban area (Calcutta). Indian J Lepr 1993; 65: 305-314.
54. Krishnan SK, Gokarn A. Study of leprosy among slum dwellers in Pune. Part II - disabilities. Indian J Public Health 1992; 36: 87-92.
55. Myint T, Htoon MT, Shwe T. Estimation of leprosy prevalence in Bago and Kawa townships using twostage probability proportionate to size sampling technique. //:// Epidemiol 1992; ai: 778-783.
56. Zhang G, Li W, Yan L, et al. An epidemiological survey of deformities and disabilities among 14257 leprosy patients in n counties. Chin Med Sei J 1992; 7: 216-220.
57. Becx-Bleuminx M. Success of the WHO multidrug therapy? Trop Geogr Med 1994; 46: 61-64.
58. Becelli LM. Evaluation of leprosy control programmes - some suggestions for operational and epidemiological assessments. WHO Bull 1970; 42: 631-634.
59. Smith WCS, Parkhe SM. Disability assessment as a measure of progress in leprosy control. Lepr Rev 1986; 57: 251-259.
60. Anonymous. Classification of disabilities resulting from leprosy. For use in control projects. WHO Bull 1969; 40: 609.
61. Brandsma JM, de Jong N, Tjepkema T. Disability grading in leprosy, suggested modifications to WHO disability grading form. Lepr Rev 1986; 57: 361-369.
62. Hasan S. An appraisal of the use of the classification of disabilities resulting from leprosy in field work and suggestions for improvement. Lepr India 1982; 54: 135-142.
63. Kulkarni VP, Kulkarni VJ, Jogaikar DG. Classification of disabilities as followed by Poona District Leprosy Committee. Indian J Lepr 1984; 56: 269-279.
64. Thappa DM. Disability grading in leprosy: current status. Indian J Lepr 1994; 66: 299-306.
65. Watson JM. WHO disability grading (letter). Lepr Rev 1985; 56: 172-175.
66. Ponnighaus IM, Borrigter G, Fine PEM, et al. Disabilities in leprosy patients ascertained in a total population survey in Karonga District, northern Malawi. Lepr Rev 1990; 61: 366-374.
67. Becelli LM, Martinz-Domingues V. Disability index for leprosy patients. WHO Bull 1971; 44: 709-713.
68. Gilbody JS. Impact of multidrug therapy on the treatment and control of leprosy. Int J Lepr 1993; 59: 458-478.
69. Smith TC, Richardus JH. Leprosy trends in northern Thailand: 1951-1990. Southeast Asian J Trop Med Public Health 1993; 24: 3-10.
70. Hagan K, Smith SE, Gyi KM, et al. The reliability of self-administration of dapsone by leprosy patients in Burma. Lepr Rev 1979; 50: 201-211.
71. Hertroijs A. A study of some factors affecting the attendance of patients in a leprosy control scheme. Int J Lepr 1974; 42: 419-427.
72. Low SJM, Pearson JMH. Do leprosy patients take dapsone regularly? Lepr Rev 1974; 45: 2.18-2.2.3.
73. Collier PJ. A study of case-holding in leprosy in Asia, based on duration of treatment. Lepr Rev 1986; 58: 549-554.
74. Anonymous. Epidemiology of leprosy in relation to control. WHO Tech Rep Ser 716, 1985.
75. Kumar A, Sivaprasad N, Anbalagan M, et al. Utilization of medical agencies and treatment compliance by urban (Madras) leprosy patients. Lepr India 1983; 55: 322-332.
76. Nigam P, Siddique MIA, Pandey NR, et al. Irregularity of treatment in leprosy patients: its magnitude and causes. Lepr India 1979; 51: 52,1-532.
77. Revankar CR, Ganapati R, Naik DD. Multidrug therapy for paucibadllary leprosy; experience in Bombay. Indian J Lepr 1985; 57: 773-779.
78. Vadher A, Lalljee M. Patient treatment compliance in leprosy: a critical review, Int J Lepr 1992; 60: 587-607.
79. Becx-Bleumink M, Berhe D, Mannetje WT. The management of nerve damage in the leprosy control services. Lepr Rev 1990; 61: 1-11.
80. Schipper A, Lubbers WJ, Hogeweg M, de Soldenhoff R. Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in Nepal. Lepr Rev 1994; 65: 235-247.
81. Becx-Bleumink M. Operational aspects of multidrug Therapy. Int J Lepr 1986; 57: 540-551. 82. Cartel JL, Spiegel A, Nguyen-Ngoc L, et al. Leprosy in French Polynesia: the possible impact of multidrug therapy on epidemiological trends. Lepr Ref .1992; 63: 223-230.
82. Cruz MD. The future of leprosy in the Dominican Republic: experience with multidrug therapy. Lepr Rev I986; 57 Suppl.: 512.7-8133.
83. De Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation of WHO-MDT of fixed duration at ALERT, ETHOPIA: the AMFES project -II. Reactions and neuritis during and after MDT in PB and MB leprosy patients. Lepr Rev 1994; 65: 330-332-
84. Mallac MJ. Onset and pattern of deformity in leprosy. Lepr Rev 1966; 57: 71-91.
85. Bresani-Silva FI. Rev Per Salnd Publica Lima 1956; 5: 79-204.
86. Anonymous. Second Expert Committee Report on Leprosy. WHO Tech Rep Ser 189,1960.
87. Shetty JN, Shivaswamy SS, Shirwadkar PS. Knowledge, attitude and practices of the community and patients regarding leprosy in Mangalore -a study. Indian J Lepr 1985; 57: 613-619.
88. Frist TF. A study of community attitudes and knowledge in relation to leprosy. Hansenologia Int 1976; 1: 184-190.
89. Noordeen SK. A look at world leprosy. Lepr Rev 1991; 62: 72-86.
90. Ashamalla L. Impact of leprosy on family and intimate relationships. Int J. Dermatol 1987; 26: 305-307.
91. Srinivasan H, Dharmendra. Deformities in leprosy (general considerations). In: Dharmendra, ed. Leprosy, Vol. i. Bombay: Kothari Medical Publishing House, 1978: Chapter 15.
92. Smith WC, Zhang G, Zheng T, et al. Prevention of impairment in leprosy; results from a collaborative project in China. Int J Lepr 1995; 63: 507-517.
93. Rose P, Waters, MFR. Reversal reactions in leprosy and their management. Lepr Rev 1991; 62: 113-121.
94. Scollard DM, Smith T, Bhoopat L, et al. Epidemiologie characteristics of leprosy reactions. Int J Lepr 1994; 62:559-567.
95. Ponnighaus JM, Boerrigter GJ. Are 18 doses of WHO/ MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Int J Lepr 1995; 63: 1-7.
96. Barnetson RS, Bjune G, Pearson JMH, Kronwall G. Antigenic heterogeneity in patients with reactions in borderline leprosy. Br Med J 1975; 4: 435-437.
97. Rees RJW, Weddell AGM. Experimental models for studying leprosy. Ann NY Acad Sei 1968; 154: 214-236.
98. Srinivasan H. Not by chemotherapy alone. Int J Lepr 1994; 62: 404-411.
99. Chopra NK, Agarwal JS, Pandya PG. Impact of multidrug therapy on leprosy in Baroda district (Gujarat). Indian J Lepr 1989; 61: 179-189.
100. Vazquez-Botet M, Sanchez JL. Erythema nodosum leprosum. Int J Dermatol 1987; 26: 436-437.
101. Sehgal VN. Reactions in leprosy. Clinical aspects. Int J Dermatol 1987; 26: 278-285.
102. Modlin RL, Gebhard F, Taylor CR, Rea TH. In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Clin Exp Imnninol 1983; 53: 17-24
103. Job CK. Nerve damage in leprosy. Int J Lepr 1989; 57: 531-539.
104. Ridley DS, Radia KB. The histological cause of reactions in borderline leprosy and their outcome. Int J Lepr 1982; 49: 383-39
105. Sehgal VN, Sharma V, Sharma VK. Comprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions. Int J Dermatol, 1989; 28: 32-35.
106. Sehgal VN, Srivastava G, Sundharam JA. Immunology of reactions in leprosy. Current status. Int J Dermatol 1988; 27: 157-162.
107. Sehgal VN, Gautam RK, Sharma VK. Immunoprofiles of reactions in leprosy. Int] Dermatol 1986; 25: 240-244.
108. Ng WL, Scollard DM, Hua A. Glomerulonephritis in leprosy: case report and review of the literature. Am J Clin Pathol 1981; 76: 65-75.
109. Bjorvatn B, Barnetson R, Kronvall G, et al. Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol 1976; 26: 388-396.
110. Chopra NK, Agrawal JS, Pandya PG. Reactions in leprosy. A study of 150 patients in a multidrug therapy project, Baroda District, Gujarat, India. Int J Dermatol 1990; 29: 490-493-
111. Tung KSK, Kim B, Bjorvatn B, et al. Discrepancy between Ciq deviation and Raji cell tests in detection of circulating immune complexes. J Infect Dis 1977; 136: 216-221.
112. Ridley M, Ridley DS. The immunopathology of erythema nodosum leprosum: the role of extravascular complexes. Lepr Rev 1983; 54: 95-107.
113. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-i beta during leprosy reactional states. Clin Exp Itnrmtnol 1991; 84: 103-108.
114. Groenen G, Janssens L, Kayembe T, et al. A prospective study on the relationship between intensive bactericidal therapy and leprosy reactions. Int J Lepr 1986; 54: 236-244.
115. Nadkarni NJ, Grugni A, Kini MS. Fixed duration MDT in paucibacillary leprosy (classical and modified). Int J Lepr 1993; 61: 25-28.
116. Katoch K, Ramanathan U, Natrajan M, et al. Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampicin. Int J Lepr 1989; 57= 458-464-
117. Naafs B, Wheate HW. The time interval between the start of anti-leprosy treatment and the development of reactions in borderline patients. Lepr Rev 1978; 49:153-157.
118. Bwire R, Kawuma HJ. Hospital-based epidemiological. study of reactions, Buluba Hospital, 1985-1989. Lepr. Rev 1993; 64: 325-329.
119. Waters ME Chemotherapy of leprosy -current status and future prospects. Trans Roy Soc Trop Med Hyg 1993; 87: 500-503-
120. Pfaltzgraff RE, Bryceson A. Clinical leprosy. In: Hastings, RC, ed. Leprosy. London: Churchill Livingstone, 1985: 165-171.
121. Boerrigter G, Ponnighaus J, Fine PEM, Wilson RJ. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 1991; 59: 255-261.
122. Gerrelts JC. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP Ann Pharmacother 1991;; 25: 525-531.
123. Pfaltzgraff RE. The management of reaction in leprosy. Int] Lepr 1989; 57: 103-109.
124. Ekambaram V, Rao MK. Changing picture of leprosy in North Arcot District, Tamil Nadu, after MDT. Indian J Lepr 1989; 61: 31-43.
125. Anonymous. Sixth Expert Committee Report on Leprosy. WHO Tech Rep Ser 768, 1988.
126. Noordeen SK. Eliminating leprosy as a public health problem; why the optimism is justified. Int J Lepr 1995; 63: 559-566.
127. Ramu G, Desikan KV. A study of scrotal biopsy in subsided cases of lepromatous leprosy. Lepr India 1979; 51: 341-347.
128. Vellut C. Ten years follow-up of lepromatous patients on DDS treatment. Lepr India 1968; 40: 111-114.
129. Waters MFR, Rees RJW, Pearson JMH, et al. Rifampicin for lepromatous leprosy: nine years' experience. Br Med J 1978; 1: 133-136.
130. Jopling WH, Ridley MJ, Bonnici E, Depasquale G. A follow-up investigation of the Malta Project. Lepr Rev 1984; 55: 247-253.
131. THELEP (Subcommittee of Clinical Trials, Scientific Working Group on the chemotherapy of Leprosy), Scientific Working Group of the UNDP, World Bank, WHO Special Programme for Research and Training in Tropical Disease. Persiting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Lepr Rev 1987; 58: 325-337.
132. Shen J. Regarding relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen, bit] Lepr 1996; 64: 79-80.
133. Ramu G. Problems of multidrug therapy. Int J Lepr 1991:63:435-445.
134. Reddy PK, Mohinuddin SK. Pattern of relapses in paucibacillary leprosy patients treated with M.D.T. (W.H.O. 1982). Indian] Lepr 1988; 60: 581-588.
135. Pattyn SR. Search for effective short-course regimens for the treatment of leprosy. Int J Lepr 1993; 61: 76-81.
136. Van Brackel W, Kist P, Noble S, O'Toole L. Relapses after multidrug therapy for leprosy: a preliminary report of 22 cases in West Nepal. Lepr Rev 1989; 60: 45-50.
137. Grugni A, Nadkarni NJ, Kini MS Mehta VR. Ralapses in paucibacillary leprosy after MDT -a clinical study. IntJ Lepr 1990; 58: 19-24.
138. Blanc L, Bobin P, Daumerie D, et al. Ralapses in multibacillary leprosy patients after stopping treatment with rifampicin-containing combined regimens. Int J Lepr 1992; 60: 525-535.
139. ALM Consensus Development Conference oft the Chemotherapy of Leprosy. Consensus development statement on the chemotherapy of leprosy. Int J Lepr 1992; 60: 19-92.
140. Anonymous. Risk of relapse in leprosy. WHO/CTD/ LEP/94-I, I994b.
141. Pavitran K. Relapse of paucibacillary leprosy after short course multidrug therapy. Indian J Lepr 1988; 60: 225-229.
142. Katoch K, Ramu, Ramanathan U, et al. Follow-up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy. Indian J Lepr 1987; 59: 36-43.
143. Cartel JL, Boutin J-P, Spiegel A, et al. Longitudinal study on relapses of leprosy in Polynesian multibacillary patients on dapsone monotherapy between 1946 and 1970. Lepr Rev 1991; 62: 186-192.
144. Smith TC, Richardus JH. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutasone, thiacetazone, isoniazide and streptomycin in the pre-MDT era. Int J Lepr 1994;62: 353-358.
145. Jakeman P. Risk of relapse in multibacillary leprosy. Lancet 1995; 345: 4-5.
146. Jamet P, Ji B. Relapses after long-term follow-up of multibacillary patients treated by WHO multidrug regimen. Int J Lepr 1994; 62: 622.
147. Lienhardt C, James P, Sow SO. Risk of relapse in multibacillary leprosy. Lancet 1995; 345: 736.
148. Maruyama G, Miller M. Physical attractiveness and personality. In: Mahrer B, ed. Progress in Experimental Research in Personality, Vol. 10. New York: Academic Press, 1981.
149. Liveneh H. On the origins of negative attitudes towards people with disabilities. Rehabilit 1982; 43: 338-347.
150. Ma H, Ye G-Y, Shu H-W, et al. Studies on social medicine and leprosy in east China. Proc CAMS and PUMC 1989; 4: 61-64.
151. Kushwah SS, Govila AK, Upadhyay S, Kushwah J. A study of social stigma among leprosy patients attending a leprosy clinic in Gwalior. Lepr India 1981; 53: 221-225.
152. Max E, Shepard DS. Productivity loss due to deformity from leprosy in India. lut J Lepr 1989; 57: 369-375.
153. Verghese A, Beig A, Senseman LA, Sundar Rao PSS, Benjamin V. A social and psychiatric study of a representative group of families in Vellore town. Indian J Med Res 1973; 61: 608-620.
154. Meyers WM. Leprosy. Dermatol Clin 1992; 10: 73-96.
155. Brasil MTLRF, Opromolla D VA, Marzliak MLC, Nogueira W. Results of a surveillance system for adverse effects of leprosy's WHO-MDT. Int J Lepr 1996; 64: 97-104-
156. Gonzalez AB, Maestre JL, Hernandez O, et al. Survey ' for secondary dapsone resistance and rifampicin resistance in Cuba. Lepr Rev 1993; 64: 1993.
157. Grosset JH, Guepla-Lauras CC, Bobin P, et al. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampicin. Int J Lepr 1989; 57: 607614.
158. Ye GE. Diagnosis of leprosy. lut J Dermatol 1988; 27: 263-264.
159. Saito H, Tomika H, Nagashima K. In vivo and in vitro activities of ofloxacin against M. leprae infection induced in mice. Int J Lepr 1986; 54: 560-562.
160. Girdhar BK. Fluoroquinones and their adverse effects. Indian J Lepr 1993; 65: 69-79.
161. Ji B, Perani BG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental M. leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 579-581.
162. Ji B, Grosset JH. Recent advances in the chemotherapy of leprosy. Lepr Rev 1990; 61: 313-329.